• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

    5/7/25 7:30:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XOMA alert in real time by email

    EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference being held May 13, 2025.

    Mr. Hughes and Mr. Sitko will participate in a fireside chat at 2:30 PM ET.  Mr. Hughes will join the "Pros and Cons of Royalty Model – Especially in Current Financing Environment" panel discussion at 4:00 PM ET.  Mr. Sitko will participate in the "Development-Stage Companies – Where do Royalty and Tech Platforms Play Fit?" panel at 5:00 PM ET.  Registration for the conference can be accessed by visiting https://ct.to/wD4ms7s.  XOMA Royalty's presentations can be accessed by visiting the investor relations section of the Company's website at www.xoma.com.  

    In addition, members of XOMA Royalty's business development team will attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held on May 20, 2025, in New York, NY.

    About XOMA Royalty Corporation

    XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.

    XOMA Investor Contact

    Juliane Snowden            

    XOMA Royalty  

    +1 646-438-9754            

    [email protected]    
    XOMA Media Contact

    Kathy Vincent

    KV Consulting & Management

    [email protected]


    Primary Logo

    Get the next $XOMA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XOMA

    DatePrice TargetRatingAnalyst
    4/17/2025$35.00Buy
    The Benchmark Company
    4/29/2024$40.00Outperform
    Leerink Partners
    10/8/2021$56.00 → $69.00Buy
    HC Wainwright & Co.
    9/9/2021$60.00 → $56.00Buy
    Aegis Capital
    9/7/2021$22.00Outperform → Neutral
    Wedbush
    9/7/2021$22.00Neutral → Underperform
    Wedbush
    6/29/2021$60.00Buy
    Aegis Capital
    More analyst ratings

    $XOMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kosacz Barbara was granted 5,971 shares (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      5/23/25 4:48:27 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wyszomierski Jack L was granted 5,971 shares, increasing direct ownership by 48% to 18,504 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      5/23/25 4:48:15 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Limber Joseph M

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      5/23/25 4:47:58 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care